Analyst Price Targets — PRME
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 7, 2024 8:07 am | Maury Raycroft | Jefferies | $15.00 | $5.40 | TheFly | Prime Medicine assumed with a Buy at Jefferies |
| April 2, 2024 4:15 pm | David Nierengarten | Wedbush | $12.00 | $6.32 | TheFly | Prime Medicine initiated with a Buy at Wedbush |
| October 9, 2023 2:19 pm | Kostas Biliouris | BMO Capital | $19.00 | $8.75 | Benzinga | Preclinical-Phase Firm Prime Medicine's Gene Editing Platform Has Potential: Analyst |
| November 14, 2022 6:19 am | — | Morgan Stanley | $23.00 | $21.12 | Benzinga | Morgan Stanley Initiates Coverage On Prime Medicine with Equal-Weight Rating, Announces Price Target of $23 |
This site can’t be displayed in an embedded view
Some publishers block loading inside other sites for security reasons. You can open the article in a new tab instead.
Latest News for PRME

MONTRÉAL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) is pleased to announce the appointment of Germain Turpin as Interim President and Chief Executive Officer of the Company. Mr. Turpin succeeds Alexandre Côté, who will step down from his position on February 28, 2026, while remaining on the Board of Directors and retaining responsibility for special projects.

CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in three upcoming conferences:

Prime Medicine (NASDAQ: PRME - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings. Profitability This table compares Prime Medicine and

Shares of Prime Medicine, Inc. (NYSE: PRME - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12

MONTREAL, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) is pleased to announce that it has secured exclusive licenses from Prime Capital Investments Inc. for the rights to certain Beach Day Every Day ("BDED") trademarks, in exchange for royalties and marketing and promotion fees. These licenses will allow Prime to use the BDED brand exclusively in connection with…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PRME.
U.S. House Trading
No House trades found for PRME.
Options Chain Settings
Changes apply instantly as you toggle. Tap Done when finished.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.
